Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.42 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | BCR | P11274 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ABL2 | P42684 | 3/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344434 | 0.90 | SRC (0.42) | SRCEGFREHMT2ERBB2 | |
| SCHEMBL6336432 | 0.86 | EHMT2 (0.39) | EGFREHMT2ERBB2 | |
| SCHEMBL6336693 | 0.83 | EGFR (0.39) | EGFREHMT2ERBB2 | |
| SCHEMBL6337395 | 0.81 | KDM4E (0.45) | EHMT2 | |
| SCHEMBL6338533 | 0.79 | SRC (0.51) | SRCABL1BCREGFRABL2 | |
| SCHEMBL6343095 | 0.77 | IRAK4 (0.38) | EGFREHMT2ERBB2 | |
| SCHEMBL6688486 | 0.76 | SRC (0.58) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL1893090 | 0.75 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL29590073 | 0.75 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5459297 | 0.73 | SRC (0.62) | SRCABL1BCREGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960580-B2 | Nitrogenous heterocyclic substituted quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1490362-A2 | (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | Millennium Pharmaceuticals, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002072578-A2 | (HOMO) PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | MILLENNIUM PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | WNK2, PDGFA, PDGFRA | SRC 228/4885ABL1 14/4885BCR 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.